Moreover, deregulation of key signaling pathways—including PI3K–AKT, RB–E2F, and MEK—as well as abnormal PD-L1 expression, are frequently observed in metastatic tumors and are associated with resistance to ICIs. This evidence concerns the gene MAP2K7 and metastatic neoplasm.